Received Apr 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | J942L | IM |
Priorix intramuscularly instead of subcutaneously administration; This non-serious case was reported by a other health professional via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a 79-year-old female patient who received MMR (Priorix) (batch number J942L, expiry date 08-NOV-2026) for prophylaxis. On 11-APR-2025, the patient received Priorix (intramuscular). On 11-APR-2025, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: Priorix intramuscularly instead of subcutaneously administration). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 11-APR-2025 Pharmacy Technician wanted to know how to proceed after giving Priorix intramuscularly instead of subcutaneously, which led to subcutaneous injection formulation administered by other route. The reporter consented to follow up. The Vaccine Administration Facility was the same as Primary Reporter.